Endocrine Abstracts

Prostate cancer is projected to be the commonest cancer by 2030, with 1 in 8 men receiving a diagnosis in their lifetime. Although there are more than 400,000 cases in Europe diagnosed each year, many new prostate cancer treatments have been introduced and patients now live with their disease for many years. Consideration of the long-term consequences of treatment is of therefore of increasing importance. More than one third of patients with prostate cancer receive androgen de...

IntroductionAromatase Inhibitors (AI) are standard therapy for hormone receptor positive breast cancers in post-menopausal patients. Unfortunately, resistance is common and previous studies from our lab suggest that the altered steroid environment may be a driver. Using label-free mass spectrometry we set out to explore the unique androgen receptor (AR) interactome that supervenes in AI resistant breast cancer and associated hyper-androgenic environment....

Abstract Unavailable...